Airsupra (budesonide/salbutamol) / AstraZeneca, Avillion - LARVOL DELTA

Efficacy Of As-needed Albuterol‒Budesonide Versus Albuterol In Participants With Mild Asthma Not On Maintenance Therapy: BATURA Post-hoc Analysis (AAAAI 2026) - "The NNT for 1 year of follow-up was 15. AIRQ score improvement from baseline to week 16 (first measurement time) was greater with albuterol–budesonide versus albuterol (least-squares Conclusions For patients with uncontrolled mild asthma on SABA-only therapy, as-needed albuterol–budesonide demonstrates early exacerbation risk reduction, with a relatively low NNT, and improved disease control versus albuterol."

Clinical • Retrospective data • Asthma • Immunology • Respiratory Diseases

Albuterol-Budesonide Treatment in Acute Airway Obstruction Provides Enhanced Lung Function Improvement for Patients With Well-Controlled and Uncontrolled Mild Asthma (AAAAI 2026) - P3 | "FEV1 overall and relative to Results 88 randomized participants receiving >1 dose of study drug were included: mean(SD) age=44.5(13.7) years; 56.8% female; 59.1% well-controlled; mean(SD) FEV1=2.462(0.540) L (76.7[7.7]% predicted); % fall in FEV1 post-mannitol=22.5(8.0%). FEV1 improvement (LSM[SE] difference) post-mannitol challenge at 480 minutes was greater with as-needed albuterol-budesonide versus albuterol for all participants by 91.19[27.37]; 95%CI [36.69–145.68] mL, p=0.001; well-controlled by 99.06[41.28]; 95%CI Conclusions Albuterol-budesonide relieves mannitol-induced acute obstruction better than albuterol over time in controlled and uncontrolled mild asthma."

Clinical • Asthma • Immunology • Respiratory Diseases

Use of as-needed Albuterol–budesonide Is Associated with a Higher Probability of Symptom-free Nights Than as-needed Albuterol in Moderate-to-Severe Asthma (AAAAI 2026) - "Similarly, for participants without study Conclusions As-needed albuterol–budesonide results in greater probability of a symptom-free night versus albuterol. This benefit occurs even among patients not experiencing exacerbations."

Asthma • Immunology • Inflammation • Respiratory Diseases

Efficacy of Albuterol-budesonide vs Albuterol in Mild Asthma on Disease Control Over Time (AAAAI 2026) - "Baseline characteristics were balanced between arms. As-needed albuterol–budesonide vs albuterol showed, at 16 weeks (84.0% of participants followed-up) and 28 weeks (72.7% followed-up), more frequent WC status (54.0% vs 48.7%, OR[95% CI]=1.2[1.04, 1.48], p=0.017; 60.0% vs 55.6%, OR=1.2[1.00, 1.47], p=0.05), and greater Conclusions These BATURA findings demonstrate as-needed albuterol–budesonide vs albuterol results in clinically important improvements in disease control in mild asthma."

Clinical • Asthma • Immunology • Respiratory Diseases

ARRIVAL: Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. (clinicaltrials.gov) - P3 | N=296 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting

Enrollment closed • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction (clinicaltrials.gov) - P3 | N=190 | Completed | Sponsor: AstraZeneca | N=21 ➔ 190

Enrollment change • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Practice changing articles: Efficacy of albuterol-budesonide inhaler compared with albuterol alone in mild asthma. (PubMed, Am J Emerg Med) - No abstract available

Journal • Review • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

AIRSA001: Anti-Inflammatory Reliever South Africa (clinicaltrials.gov) - P3 | N=1038 | Recruiting | Sponsor: University of KwaZulu | Enrolling by invitation ➔ Recruiting | Trial completion date: May 2026 ➔ Dec 2028 | Trial primary completion date: May 2025 ➔ Dec 2028

Enrollment status • Trial completion date • Trial primary completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

ANCHOR: Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care (clinicaltrials.gov) - P4 | N=1507 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting

Enrollment closed • HEOR • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

DARWIN: Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma (clinicaltrials.gov) - P4 | N=101 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting

Enrollment closed • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

As-Needed Albuterol-Budesonide in Mild Asthma. (PubMed, Pediatrics) - No abstract available

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Albuterol-budesonide Treatment in Acute Airway Obstruction: Onset and Duration of Lung Function and Symptom Improvement (ACAAI 2025) - P3 | "Treatments showed similar adverse event rates. Conclusions Albuterol-budesonide relieves acute obstruction as-fast-as albuterol alone, providing nominally greater lung function improvement over time and rapid, sustained dyspnea relief."

Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Combination Short-Acting Bronchodilator and Inhaled Corticosteroid Rescue Therapy (the ANCHOR Study): Rationale and Design (ACAAI 2025) - "Results/Conclusions ANCHOR evaluates the changes in annualized asthma exacerbation rates after switching rescue therapy to a single albuterol plus budesonide inhaler among participants with asthma using health insurance claims data. The unique study model with minimal intervention and utilizing real-world claims data enables researchers to understand treatment patterns and drug effectiveness in the real-world setting."

Asthma • Immunology • Respiratory Diseases

Treatment for Mild Asthma: What Matters to Providers (ACAAI 2025) - "Specialists were more likely to utilize MART therapy than generalists (budesonide/formoterol: 62.5% vs. 60.0% p 0.002, mometasone/formoterol 58.5% vs. 34.8% p 0.019). Similarly, specialists were more likely to prescribe budesonide-albuterol for reliever therapy than generalists (20.1% vs. 4.5%, p<0.001), and attendings more than trainees (17.5% vs. 6.2%, p 0.025)...Lastly, specialists are more likely to utilize asthma action plans (63.5% vs. 43.4%, p 0.030). Conclusion Significant heterogeneity exists in the definition and treatment of mild asthma."

Asthma • Gynecology • Immunology • Obstetrics • Pediatrics • Respiratory Diseases

Use of As-needed Albuterol-budesonide versus Albuterol Before and After a Severe Exacerbation: BATURA Post-hoc Analysis (ACAAI 2025) - P3 | "Numerically, less ALB–BUD versus ALB was used in the two weeks before and after an exacerbation ( Figure ). Conclusion ALB–BUD versus ALB numerically reduced the overall use of rescue inhalations surrounding an exacerbation among patients with mild asthma."

Retrospective data • Asthma • Immunology • Respiratory Diseases

Albuterol–budesonide Reduces Exacerbations in Uncontrolled Mild Asthma With or Without Exacerbation History-based Risk (ACAAI 2025) - "Conclusion Patients with mild asthma and symptoms, regardless of prior-year exacerbation history, are at risk for future-year exacerbations. Albuterol–budesonide reduces exacerbation risk relative to albuterol, whether lack of control is based on IMP-only or IMP+risk."

Late-breaking abstract • Asthma • Immunology • Respiratory Diseases

In poorly controlled mild asthma, as-needed budesonide plus albuterol is more effective than albuterol alone. (PubMed, Recenti Prog Med) - No abstract available

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

TUSSIVE SYNCOPE IN A PATIENT WITH INFLUENZA B AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (CHEST 2025) - "After testing positive for Influenza B, he was prescribed oseltamivir. He was advised to continue his COPD medications, including triple therapy (fluticasone, umeclidinium, vilanterol) and ipratropium/albuterol inhalers...He returned to his primary care provider 3 days later, who started him on amoxicillin-clavulanate, benzonatate, and prednisone...He was treated with budesonide and albuterol nebulizers, tiotropium/olodaterol inhaler, IV methylprednisolone, diphenhydramine plus hydrocodone, and azithromycin... Patients with influenza and comorbidities such as COPD and coronary artery disease should be assessed for signs of syncope, particularly in those with prolonged and intense coughing episodes. Additionally, patient education and close monitoring are crucial to reduce the risk of fall-related injuries."

Clinical • Cardiovascular • Chronic Cough • Chronic Obstructive Pulmonary Disease • Coronary Artery Disease • Cough • Gastroenterology • Gastroesophageal Reflux Disease • Hypertension • Hypotension • Immunology • Infectious Disease • Influenza • Musculoskeletal Diseases • Obstructive Sleep Apnea • Orthopedics • Pulmonary Disease • Respiratory Diseases • Sleep Disorder

As-Needed Albuterol-Budesonide in Mild Asthma. (PubMed, N Engl J Med) - No abstract available

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

As-Needed Albuterol-Budesonide in Mild Asthma. Reply. (PubMed, N Engl J Med) - No abstract available

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

ALBUTEROL-BUDESONIDE COMBINATION THERAPY IN ASTHMA: A SYSTEMATIC REVIEW (CHEST 2025) - "Albuterol-budesonide combination therapy significantly improves asthma control compared to albuterol alone, as evidenced by enhanced ACQ responses in the reviewed trials. CLINICAL IMPLICATIONS: This dual-action approach offers rapid symptom relief along with sustained anti-inflammatory benefits, suggesting that it may be a valuable option for patients with moderate to severe asthma who require both immediate and long-term control."

Combination therapy • Review • Asthma • Immunology • Respiratory Diseases

AS-NEEDED ALBUTEROL-BUDESONIDE VS AS-NEEDED ALBUTEROL DECREASES SEVERE EXACERBATION RISK AND IMPROVES ASTHMA CONTROL AT 16 WEEKS IN MILD ASTHMA: BATURA POST-HOC ANALYSES (CHEST 2025) - P3 | "Sixteen weeks of as-needed albuterol-budesonide reduced severe exacerbation risk and improved asthma control versus as-needed albuterol in patients >12 years with mild asthma. CLINICAL IMPLICATIONS: BATURA in mild asthma and MANDALA in moderate-to-severe disease demonstrated sever exacerbation risk reduction as early as 16 and 12 weeks, respectively. Patients across the severity spectrum switching from albuterol to albuterol-budesonide rescue therapy can anticipate early reductions in exacerbation risk."

Retrospective data • Asthma • Immunology • Respiratory Diseases

ASTHMA CONTROL IN PARTICIPANTS WITH MILD ASTHMA ENROLLED IN THE BATURA CLINICAL TRIAL: IMPAIRMENT AND RISK PROFILES AT RANDOMIZATION (CHEST 2025) - P3 | "Uncontrolled patients treated for mild asthma have a heavy symptom burden impacting their daily lives despite most not experiencing prior-year exacerbations. CLINICAL IMPLICATIONS: Clinicians should recognize that uncontrolled patients treated for mild asthma who have not experienced prior-year exacerbations may be at risk of future exacerbations and, as demonstrated in BATURA, can benefit from a switch from SABA-only to albuterol–budesonide anti-inflammatory rescue therapy."

Clinical • Asthma • Immunology • Respiratory Diseases

DARWIN: Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma (clinicaltrials.gov) - P4 | N=100 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Nov 2025 ➔ Feb 2026 | Trial primary completion date: Nov 2025 ➔ Feb 2026

Trial completion date • Trial primary completion date • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Spontaneous Unilateral Epistaxis and Telangiectasia presenting similarly to Hereditary Hemorrhagic Telangiectasia (AAO-HNSF 2025) - "His medications included albuterol, budesonide-formoterol, aspirin, amlodipine, rosuvastatin, and omeprazole. This case underscores the challenges of diagnosing HHT-like conditions when genetic testing fails to identify known pathogenic variants. The findings highlight limitations in current genetic testing for distinguishing HHT from mimicking conditions or atypical cases. Investigation into other cases of unilateral epistaxis and telangiectasias is warranted to enhance diagnostic clarity and improve management strategies."

Anemia • Cardiovascular • CNS Disorders • Coronary Artery Disease • Hematological Disorders • Immunology • Vascular Neurology • ACVRL1 • SMAD4